Pharmacist-Led Care for Cardiovascular Disease (INCLUDE Trial)

N/A

Waitlist Available

Research Sponsored by Intermountain Health Care, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Documentation of an ASCVD diagnosis, by one of the following: Coronary artery disease (Primary inpatient CAD diagnosis during index encounter; Primary inpatient MI diagnosis during index encounter; PCI during index encounter; or CABG during index encounter), Cerebrovascular accident (Primary inpatient ischemic stroke diagnosis during index encounter; Carotid endarterectomy during index encounter; or Carotid stent during index encounter), Peripheral arterial disease (Bypass or percutaneous intervention during index encounter)

Be older than 18 years old

Must not have

Receipt of or expected receipt of palliative care, expected discharge to hospice, or long-term care facility (i.e., skilled nursing facility)

Patient age under 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

"This trial will screen patients who had a heart or stroke event at an Intermountain hospital. Eligible patients will be randomly assigned to receive pharmacist-driven care to manage their cholesterol levels or not. Patients

Who is the study for?

This trial is for patients who have had an event related to atherosclerotic cardiovascular disease at an Intermountain hospital. They should be willing to potentially receive LDL-C management from a clinical pharmacy team and follow up for one year.

What is being tested?

The study compares two approaches: one where patients get targeted care for managing their LDL cholesterol through a pharmacist-led program, versus usual care without this specialized intervention. The goal is to see if the pharmacy program helps more people reach ideal LDL levels.

What are the potential side effects?

Since the interventions involve standard care or additional monitoring and guidance by pharmacists rather than new medications, no direct side effects are expected from participating in this trial.